E-Paper
Morgan Stanley cuts India's GlaxoSmithKline Pharma to 'under-weight'
Morgan Stanley cut its rating on India's GlaxoSmithKline Pharmaceuticals Ltd to "under-weight" from "equal-weight", citing expectations the drug maker will post modest growth and saying margin expansion looked unlikely.
Updated on: Feb 28, 2013, 10:25:10 IST
Share via
Copy link
Morgan Stanley cut its rating on India's GlaxoSmithKline Pharmaceuticals Ltd to "under-weight" from "equal-weight", citing expectations the drug maker will post modest growth and saying margin expansion looked unlikely.
GlaxoSmithKline's shares are also constrained by its pricing policy and "full" valuations, the broker added.
Stay updated with the latest Business News on Petrol Price, Gold Rate, Silver Rates, Diesel Prices along with Income Tax Calculator
